Loading
HLD-0915 (JNJ-101556143) is an experimental oral heterobifunctional small molecule from Halda Therapeutics, in phase 1 trials for metastatic prostate cancer.
HLD-0915 (JNJ-101556143) (HLD-0915, JNJ-101556143) is an oral heterobifunctional small molecule (RIPTAC) from Halda Therapeutics, with Johnson & Johnson as acquirer. A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance. Its furthest stage is phase 1, for metastatic prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1/2 NCT06800313 recruiting (sponsor Janssen Research & Development), and an arm in NCT06095089 (Janssen combination study). Johnson & Johnson completed the acquisition of Halda on 29 December 2025. Whether it works in people has not been established unless a trial below reports it.
A once-daily oral therapy built on the RIPTAC platform, which brings a tumour-specific protein together with a protein the cell needs to survive, to kill cancer cells selectively and overcome resistance.
1.One arm of HLD-0915 (JNJ-101556143) binds its target on the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HLD-0915" OR ABSTRACT:"HLD-0915" OR TITLE:"JNJ-101556143" OR ABSTRACT:"JNJ-101556143") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLD-0915 (JNJ-101556143), not a curated reading list.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/